Stoked Bio Secures $2.5M to Fuel AI War on Superbugs and Cancer

HAMILTON, ON – May 01, 2026 – Canadian biotechnology firm Stoked Bio Inc. has successfully closed an oversubscribed $2.5 million seed funding round, signaling strong investor confidence in its mission to revolutionize drug discovery for some of the world's most challenging diseases. The financing, sourced almost entirely from Ontario-based angel investors, will accelerate the company's pipeline of novel therapeutics for drug-resistant infections, aggressive cancers, and neurodegenerative disorders.

Stoked Bio, a spin-out from McMaster University, is not just another company riding the artificial intelligence wave. It aims to fundamentally reshape how new medicines are found by combining a proprietary AI platform with a 'biology-first' methodology. This fresh capital injection will advance its most promising drug candidates toward critical proof-of-concept stages, setting the stage for future pharmaceutical partnerships.

"Stoked Bio was founded on the idea of tackling diseases with a real need for new therapeutic options," said Jeff Skinner, CEO of Stoked Bio, in a statement. "This financing, in combination with significant non-dilutive funding, provides us with runway to advance our growing portfolio of novel drug candidates to late-stage proof of concept and initiate partnering discussions."

Beyond the Hype: A 'Biology-First' AI Engine

At the heart of Stoked Bio's strategy is MOSAIC™, its unique AI-guided discovery platform developed in the lab of founder and Chief Scientific Officer, Dr. Jon Stokes. Unlike many AI drug discovery models that rely on vast, pre-existing, and potentially biased public datasets, Stoked Bio's approach starts with biology. The company generates its own high-quality, disease-specific data by exposing disease samples to massive chemical libraries and observing the biological effects.

This method allows the AI to learn from real-world biological responses, identifying compounds with genuine therapeutic effects rather than just statistical correlations. It's a crucial distinction that experts believe could overcome a major hurdle in AI-driven medicine: the 'garbage in, garbage out' problem. By creating its own bespoke training data, Stoked Bio aims to uncover non-obvious drug candidates that traditional screening methods and data-scraping AI might miss.

Dr. Stokes, an Assistant Professor at McMaster University and a former Banting postdoctoral fellow at the Broad Institute of MIT and Harvard, is a leading figure in using machine learning to find new medicines. His previous work includes the AI-driven discovery of abaucin, a potent compound targeting Acinetobacter baumannii, a bacterium on the World Health Organization's (WHO) critical priority list. This foundational science, which underpins Stoked Bio's work, has been published in prestigious journals like Nature Microbiology, lending significant scientific credibility to the company's ambitious goals.

A Multi-Front War on Untreatable Diseases

The $2.5 million in funding will fuel a diverse and urgently needed therapeutic pipeline. The company is taking aim at diseases where current treatments are failing or non-existent, creating a portfolio that addresses several major public health crises.

Its lead candidate, Enterololin, is a novel antibiotic that selectively targets Enterobacteriaceae, a family of bacteria designated as a 'critical' priority by the WHO due to widespread resistance to last-resort antibiotics. Beyond tackling life-threatening infections, Enterololin's precision targeting offers another significant advantage: it has the potential to treat microbiome-related conditions like Crohn's disease, recurrent urinary tract infections, and hepatic encephalopathy without causing the collateral damage to beneficial gut bacteria associated with broad-spectrum antibiotics.

Stoked Bio is also advancing a program against glioblastoma, the most common and lethal form of brain cancer. With a median survival of just 12-16 months and a near-zero five-year survival rate, glioblastoma has seen tragically little therapeutic progress in decades. The company's AI platform is being deployed to find new ways to attack this notoriously difficult-to-treat cancer.

Further expanding its scope, the company is developing a novel treatment approach for Parkinson's Disease, a progressive neurodegenerative disorder affecting millions worldwide. In parallel, a collaboration with the University of Guelph is underway to combat the growing threat of drug-resistant fungal infections, another area highlighted by the WHO as a major public health concern.

Ontario's Bet on a Homegrown Innovator

The fact that 99% of the seed round was financed by Ontario investors is a powerful testament to the strength of the province's life sciences ecosystem. It reflects a deliberate strategy by local investors and government bodies to nurture and retain high-potential scientific innovation within Canada.

Stoked Bio has been an active participant in this ecosystem, benefiting from support programs like the Southern Ontario Pharmaceutical and Health Innovation Ecosystem (SOPHIE), which is funded by the Federal Economic Development Agency for Southern Ontario (FedDev Ontario). The company has also engaged with IP Ontario and has been recognized in regional competitions, building a groundswell of local support.

This homegrown backing provides more than just capital; it creates a network of support that helps companies navigate the complex path from lab discovery to clinical reality. For Stoked Bio, it means having a committed investor base that understands the long-term vision and the potential global impact of its technology.

The leadership team reflects a potent combination of scientific vision and commercial acumen. Dr. Stokes provides the deep expertise in AI and antimicrobial discovery, while CEO Jeff Skinner brings over two decades of pharmaceutical industry experience in business development and strategic partnering. This blend of science and business is critical for translating breakthrough research into patient-ready therapies.

As Stoked Bio deploys its new capital, the broader medical and scientific communities will be watching closely. The company is not just developing drugs; it is testing a new paradigm for discovery, one that could significantly increase the odds of success and accelerate the delivery of new hope for patients with the highest unmet needs.